The investigation by Pomerantz LLP centers on whether Sellas and its executives engaged in securities fraud or other unlawful business practices regarding the handling of this data. On August 28, 2026, the company’s share price fell $2.00 to close at $13.21 following the news of the undisclosed trial developments. Investors who suffered losses are now being urged to contact Danielle Peyton at the firm to discuss potential class action participation.
Pomerantz LLP Probes Sellas Life Sciences Following Clinical Trial Delay
A 13.15% drop in Sellas Life Sciences stock followed reports that the company failed to disclose results from its phase 3 clinical trial for Galinpepimut-S. The decline occurred after the study reached its 80th patient death, a pre-specified milestone that should have triggered an immediate public release of findings.
Sellas has not yet issued a formal response regarding the status of the Galinpepimut-S trial results or the allegations surrounding the delay. Pomerantz LLP, a firm with a history of securities litigation spanning over eight decades, is currently evaluating the timeline of the company’s disclosures to determine if fiduciary duties were breached. The firm maintains offices in major financial hubs, including New York, London, and Tel Aviv, and specializes in recovering damages for victims of corporate misconduct.
Comments (0)
No comments yet. Be the first!